Gastrointestinal disorders and dabigatran

References

• Gums JG. Place of dabigatran in contemporary pharmacotherapy. Pharmacotherapy 2011;31:335–7.
   PubMedGoogle Scholar
• Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis 2011; [Epub ahead of print].
   PubMedGoogle Scholar
• Marongiu F, Tosetto A, Palareti G. Special indications for vitamin K antagonists: a review. Intern Emerg Med 2011; [Epub ahead of print].
   Google Scholar
• European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Camm AJ, Kirchhof P, Lip GY, Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369–429.
   PubMed Web of Science ®Google Scholar
• Galanis T, Thomson L, Palladino M, Merli GJ. New oral anticoagulants. J Thromb Thrombolysis 2011; [Epub ahead of print].
   Google Scholar
• Faltas B. A new anticoagulant for a new era: review of recent data on dabigatran etexilate. Clin Adv Hematol Oncol 2010;8:697–702.
   PubMedGoogle Scholar
• Garnock-Jones KP. Dabigatran etexilate: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Am J Cardiovasc Drugs 2011;11:57–72.
   PubMed Web of Science ®Google Scholar
• Edwards D. Dabigatran v warfarin. Compare with higher standard. BMJ 2010;341.
   Google Scholar
• Eisert WG, Hauel N, Stangier J, Wienen W, Clemens A, van Ryn J. Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. Arterioscler Thromb Vasc Biol 2010;30:1885–9.
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Quinlan DJ, Eikelboom JW. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. Annu Rev Med 2011;62:41–57.
   PubMed Web of Science ®Google Scholar
• Iqbal Z, Cohen M. Emerging antithrombotic agents: what does the intensivist need to know? Curr Opin Crit Care 2010;16:419–25.
   PubMedGoogle Scholar
• Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008;36:386–99.
   PubMed Web of Science ®Google Scholar
• Stangier J, Eriksson BI, Dahl OE, Ahnfelt L, Nehmiz G, Stähle H, Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 2005;45:555–63.
   PubMed Web of Science ®Google Scholar
• Lee CJ, Ansell JE. Direct thrombin inhibitors. Br J Clin Pharmacol 2011.
   Google Scholar
• Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost 2009;15(Suppl 1):9S–16S.
   PubMed Web of Science ®Google Scholar
• Stangier J, Rathgen K, Stähle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010;49:259–68.
   PubMed Web of Science ®Google Scholar
• van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Dabigatran etexilate–a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103:1116–27.
   PubMed Web of Science ®Google Scholar
• van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Dabigatran etexilate–a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103:1116–27.
   PubMed Web of Science ®Google Scholar
• Verma AK. Dabigatran etexilate: a new thrombin inhibitor. Med J Aust 2010;192:407–12.
   PubMedGoogle Scholar
• Eisert WG, Hauel N, Stangier J, Wienen W, Clemens A, van Ryn J. Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. Arterioscler Thromb Vasc Biol 2010;30:1885–9.
   PubMed Web of Science ®Google Scholar
• Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008;36:386–99.
   PubMed Web of Science ®Google Scholar
• Stangier J, Stähle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008;47:47–59.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139–51.
   PubMed Web of Science ®Google Scholar
• Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342–52.
   PubMed Web of Science ®Google Scholar
• Ezekowitz MD, Wallentin L, Connolly SJ, Parekh A, Chernick MR, Pogue J, RE-LY Steering Committee and Investigators. Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. Circulation 2010;122:2246–53.
   PubMed Web of Science ®Google Scholar
• Piccini JP, Lopes RD, Mahaffey KW. Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation. Curr Opin Cardiol 2010;25:312–20.
   PubMed Web of Science ®Google Scholar
• Ford AC, Marwaha A, Lim A, Moayyedi P. What is the prevalence of clinically significant endoscopic findings in subjects with dyspepsia? Systematic review and meta-analysis. Clin Gastroenterol Hepatol 2010;8:830–7.
   PubMed Web of Science ®Google Scholar
• Talley NJ, Vakil N; Practice Parameters Committee of the American College of Gastroenterology. Guidelines for the management of dyspepsia. Am J Gastroenterol 2005;100:2324–37.
   PubMed Web of Science ®Google Scholar
• Bytzer P. Dyspepsia as an adverse effect of drugs. Best Pract Res Clin Gastroenterol 2010;24:109–20.
   PubMedGoogle Scholar
• Pearson RK, Hauben M, Goldsmith DI, Gould AL, Madigan D, O'Hara DJ, Influence of the MedDRA hierarchy on pharmacovigilance data mining results. Int J Med Inform 2009;78:e97–e103.
   PubMed Web of Science ®Google Scholar
• Mozzicato P. Standardised MedDRA queries: their role in signal detection. Drug Saf 2007;30:617–19.
   PubMed Web of Science ®Google Scholar
• Kang JY. Systematic review: geographical and ethnic differences in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2004;20:705–17.
   PubMedGoogle Scholar
• Jung HK. Epidemiology of gastroesophageal reflux disease in Asia: a systematic review. J Neurogastroenterol Motil 2011;17:14–27.
   PubMed Web of Science ®Google Scholar
• Hankey GJ, Eikelboom JW. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation 2011;123:1436–50.
   PubMed Web of Science ®Google Scholar
• Emmett M. Recurrent tartaric acid acidosis? Kidney Int 2011;79:258–9.
   PubMedGoogle Scholar
• Spiller GA, Story JA, Furumoto EJ, Chezem JC, Spiller M. Effect of tartaric acid and dietary fibre from sun-dried raisins on colonic function and on bile acid and volatile fatty acid excretion in healthy adults. Br J Nutr 2003;90:803–7.
   PubMed Web of Science ®Google Scholar
• Spiller GA, Story JA, Lodics TA, Pollack M, Monyan S, Butterfield G, Effect of sun-dried raisins on bile acid excretion, intestinal transit time, and fecal weight: a dose-response study. J Med Food 2003;6:87–91.
   PubMedGoogle Scholar
• Krapez-Kordis M, Abram V, Kac M, Determination of organic acids in white wine by RP-HPLC. Food Technol Biotechnol 2001;39:93–9.
   Google Scholar
• Greenrod W, Fenech M. The principal phenolic and alcoholic components of wine protect human lymphocytes against hydrogen peroxide- and ionizing radiation-induced DNA damage in vitro. Mutagenesis 2003;18:119–26.
   PubMed Web of Science ®Google Scholar
• Garrido-Delgado R, López-Vidal S, Arce L, Valcárcel M. Differentiation and identification of white wine varieties by using electropherogram fingerprints obtained with CE. J Sep Sci 2009;32:3809–16.
   PubMedGoogle Scholar
• Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888–99; No abstract available. Erratum in: N Engl J Med 1999 Aug 12;341:548.
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; [Epub ahead of print].
   Google Scholar